Home Celyad Treats First Patient of Second Cohort in NKG2D Car T-Cell Phase I Trial
 

Keywords :   


Celyad Treats First Patient of Second Cohort in NKG2D Car T-Cell Phase I Trial

2015-12-01 07:59:13| Semiconductors - Topix.net

Celyad , a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, today announced the infusion of the first patient of the second cohort of its Phase I clinical trial evaluating the Company's NKG2D CAR T-Cell therapy in acute myeloid leukaemia and multiple myeloma indications. Dr. Christian Homsy, CEO of Celyad, said : " The treatment of the first patient enrolled in the second cohort of our first-in-man Phase I trial evaluating NKG2D CAR T-Cells demonstrates continued progress in developing our lead immune-oncology program.

Tags: car trial phase patient

Category:Electronics and Electrical

Latest from this category

All news

»
05.11Boeing strike ends as workers back 38% pay rise deal
05.11Tropical Storm Rafael Public Advisory Number 6A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Graphics
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Forecast Discussion Number 6
More »